TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 5 of the 33 sources its claims cite were checked for support.
Abstract
Cellular mechanisms that mediate steatohepatitis, an increasingly prevalent condition in the Western world for which no therapies are available, are poorly understood. Despite the fact that its synthetic agonists induce fatty liver, the liver X receptor (LXR) transcription factor remains a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory activities. Here we show that tetratricopeptide repeat domain protein 39B (Ttc39b, C9orf52) (T39), a high-density lipoprotein gene discovered in human genome-wide association studies, promotes the ubiquitination and degradation of LXR. Chow-fed mice lacking T39 (T39−/−) display increased high-density lipoprotein cholesterol levels associated with increased enterocyte ATP-binding cassette transporter A1 (Abca1) expression and increased LXR protein without change in LXR messenger RNA. When challenged with a high fat/high cholesterol/bile salt diet, T39−/− mice or mice with hepatocyte-specific T39 deficiency show increased hepatic LXR protein and target gene expression, and unexpectedly protection from steatohepatitis and death. Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr−/−T39−/−) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprotein, and reduced atherosclerosis. In addition to increasing hepatic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic sterol regulatory element-binding protein 1 (SREBP-1, ADD1) processing. This is explained by an increase in microsomal phospholipids containing polyunsaturated fatty acids, linked to an LXRα-dependent increase in expression of enzymes mediating phosphatidylcholine biosynthesis and incorporation of polyunsaturated fatty acids into phospholipids. The preservation of endogenous LXR protein activates a beneficial profile of gene expression that promotes cholesterol removal and inhibits lipogenesis. T39 inhibition could be an effective strategy for reducing both steatohepatitis and atherosclerosis.
Overview
CoChat Summary
TL;DR
TTC39B (T39) promotes ubiquitination and degradation of LXR; T39 deficiency stabilizes LXR protein and protects mice from both steatohepatitis and atherosclerosis. The mechanism couples increased cholesterol removal with inhibited SREBP-1 processing and lipogenesis.
Key findings
- T39 deficiency increased HDL cholesterol by ∼22% in chow-fed mice and by 42% after HF/HC/BS diet, with a 45% increase in ApoA-1; this was linked to increased intestinal Abca1 and post-transcriptional LXR protein induction.
- In HF/HC/BS-fed T39−/− mice, there was a 4-fold reduction in mortality (p<0.05), decreased ALT, less hepatic TG and cholesteryl ester accumulation, fewer inflammatory foci, less ballooning, and less fibrosis; protection was due to hepatic T39 deficiency and was LXRα-dependent.
- T39 deficiency inhibited hepatic SREBP-1 processing and reduced lipogenic gene expression and TG synthesis, associated with LXRα-dependent induction of Insig2a, Pcyt1a, Cept1, and Lpcat3, a 30% increase in microsomal phosphatidylcholine, and increased PUFA content in phospholipids.
- In WTD-fed Ldlr−/−T39−/− mice, T39 deficiency decreased fatty liver, increased HDL, decreased LDL, and reduced atherosclerotic lesion area and lesion complexity.
Methods
- Mouse models included whole-body T39−/−, tissue-specific Villin-Cre and Albumin-Cre T39fl/fl, Ldlr−/−T39−/−, and Lxrα−/−T39−/− mice; both sexes, 10–20 weeks old, fed chow, HF/HC/BS diet (7.5% cocoa butter, 1.25% cholesterol, 0.5% sodium cholate), or WTD (21% milk fat, 0.15% cholesterol), with blinded measurements.
- Analyses included lipoprotein/cholesterol/TG assays, Western blotting, gene expression, [3H]cholesterol secretion from enterocytes, NASH histological grading, dietary cholesterol absorption, GC-MS sterol/oxysterol measurement, in vivo lipogenesis, lipidomics, atherosclerosis quantification, ChIP, co-immunoprecipitation, GW3965-affinity LXR pulldown, and LXRα turnover assays.
- Statistics used mean ± SEM, two-tailed Student t-test or two-way ANOVA with Bonferroni post hoc, p<0.05 significance, and Grubbs’ test for outliers.
Limitations
- The paper does not state limitations explicitly. Evident from the text: all functional and therapeutic conclusions come from mouse models and cell culture, with no human interventional or clinical validation.
- Several mechanistic links are proposed rather than fully established; the text notes “there must be a separate more physiologically relevant mechanism regulating SREBP-1 maturation” and that increased PC synthesis/PUFA incorporation “may be a major factor” inhibiting NAFLD.
- No pharmacological T39 inhibitor was tested in vivo; the therapeutic implication that “T39 inhibition could be an effective strategy” remains untested in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 24 Not checked · 128 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This suggests that under inflammatory conditions induced by the HF/HC/BS diet, the liver also contributes to the HDL phenotype of T39-/- mice, consistent with the previous report that T39 knockdown mediated by adenovirus, which targets the liver and is inflammatory, raised HDL2.”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Partly supportedcites [2] Teslovich TM Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 707 713 2010 20686565 PMC3039276 sourceExperimental — accuracy not yet measured
The clause the citation is offered for is the 'previous report' that T39 knockdown mediated by a liver-targeting, inflammatory viral vector raised HDL2. Teslovich et al. (Biological Relevance of GWAS Loci) do report that knockdown of the mouse orthologue Ttc39b via a viral vector (~50% transcript reduction) significantly raised plasma HDL-C (19% at four days, 14% at seven days), consistent with the liver eQTL for TTC39B — so the core attribution (T39 knockdown raises HDL in mice) is supported. However, our copy reports total plasma HDL-C, not the HDL2 subspecies, and nowhere describes the vector as inflammatory; the liver targeting is implied by the liver eQTL and the viral-vector approach used for the other genes rather than stated for Ttc39b. The HDL2-subspecies and inflammation parts of the claim are therefore not supported by this source. (LLM, conf=0.75)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is longstanding evidence that the intestine makes a substantial contribution to the production of HDL5,6.”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Supportedcites [5] Brunham LR Intestinal ABCA1 directly contributes to HDL biogenesis in vivo The Journal of clinical investigation 116 1052 1062 10.1172/JCI27352 2006 16543947 PMC1401485 source
The Abstract and Discussion of Brunham et al. (2006) state that intestinal ABCA1 contributes approximately 30% of the steady-state plasma HDL cholesterol pool in mice and 'establish a critical role for intestinal ABCA1 in plasma HDL biogenesis in vivo'; the Figure 7 legend likewise concludes the intestine is 'crucially involved in the maintenance of plasma HDL levels'. The Introduction adds that the intestine contributes roughly 50% of total plasma apoA-I and reviews earlier (Roheim 1966; Green 1978; Forester 1983) evidence of intestinal HDL secretion, consistent with the citing sentence's 'longstanding evidence'. The quantitative contribution is bounded by the mouse model used, which the citing sentence does not specify, but the attributed point — a substantial intestinal contribution to HDL production — is stated in our copy. (LLM, conf=0.85)
- Not checked yetcites [6] Wu AL Windmueller HG Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat The Journal of biological chemistry 254 7316 7322 1979 457683 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We also observed induction of other intestinal LXR target genes including Inducible degrader of LDLR (Idol, Mylip1)8 (ED Fig 2d).”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Supportedcites [8] Zelcer N Hong C Boyadjian R Tontonoz P LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Science 325 100 104 2009 19520913 PMC2777523 source
Passage 3 (Results) identifies the LXR target gene the citing sentence credits to ref 8: 'LXR agonists induced Idol expression... Treatment of mice with GW3965 induced expression of Idol in multiple tissues, including spleen, intestine and adrenals (Fig. 2B)', and gives exactly the nomenclature the claim uses — 'variably referred to as Mir and Mylip... we propose... be renamed Idol (for Inducible Degrader of the LDLR)'. Passage 1 repeats the intestinal induction, and passage 2 confirms the intestine as a tissue where LXR-Idol signalling is prominent. The citing authors' own observation in T39-/- mice is theirs; the citation is offered only to identify Idol/Mylip1 as an intestinal LXR target gene, which our copy states directly. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The reduction in TG synthesis was accompanied by decreased expression of many lipogenic genes, including Scd1, Elovl5, Acetyl-CoA carboxylase α (Accα), Glycerol-3-phosphate acyltransferase (Gpat1, Gpam), and Glucose-6-phosphate dehydrogenase (G6pd), as well as Patatin-like phospholipase domain-containing protein 3 (Pnpla3, Adiponutrin), which is an SREBP-1 target implicated in human hepatic steato”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Partly supportedcites [17] Huang Y A feed-forward loop amplifies nutritional regulation of PNPLA3 Proc Natl Acad Sci U S A 107 7892 7897 2010 20385813 PMC2867902 sourceExperimental — accuracy not yet measured
Our copy supports only the trailing characterization of Pnpla3: the Transcriptional Regulation section (and Fig. 2 legend) shows PNPLA3/adiponutrin is a direct SREBP-1c target (up-regulated ~90-fold by refeeding, blocked in Scap-/- and SREBP-1c-/- mice, SREBP-1 chromatin peak in intron 1), and the opening paragraph credits the I148M variant with conferring susceptibility to hepatic TG deposition. The main attributed observation is not in this paper: no passage mentions Scd1, Elovl5, Accα, Gpat1 or G6pd (searched those gene names plus 'lipogenic gene expression'), and the only experiment here that reduces TG synthesis — triacsin C in oleate-treated HuH-7 cells (Posttranslational Regulation of PNPLA3 by Fatty Acids; reiterated in the Abstract and Discussion) — reports the opposite for PNPLA3, namely that the fatty-acid-induced increase in PNPLA3 persisted despite blocked TG synthesis, with oleate raising protein mass without any change in PNPLA3 mRNA. So the gene panel and the coupling of reduced TG synthesis to decreased Pnpla3 expression are not supported by this source. (LLM, conf=0.78)
- Could not verifycites [18] Romeo S Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 1461 1465 2008 18820647 PMC2597056 sourceExperimental — accuracy not yet measured
Our copy of Romeo et al. (2008) is a human genetic association study (Dallas Heart Study admixture mapping/resequencing plus ARIC replication); no passage reports suppressing hepatic TG synthesis or measures expression of Scd1, Elovl5, Accα, Gpat1 or G6pd — searches for 'lipogenic genes', 'SREBP-1', 'adiponutrin mRNA expression in mouse liver' returned only the discussion of nutritional regulation of PNPLA3 (Abstract, p. ~n/p: 'mRNA levels are low in the fasted state and increase dramatically with carbohydrate feeding', credited to refs 20 and 21, Baulande et al. 2001 and Lake et al. 2005). That passage addresses fasting/feeding regulation, not a reduction in TG synthesis, so it neither supports nor contradicts the attributed expression finding. The copy does support the separate point that PNPLA3-I148M is associated with increased hepatic fat content in humans (Abstract, Fig. 1b/Fig. 2b), but the expression claim itself is not addressed anywhere in our copy. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The livers of Albumin-Cre(+)T39fl/fl mice had less perisinusoidal and periportal fibrosis compared to the T39fl/fl and Villin-Cre(+)T39fl/fl mice (Fig 1g and ED Fig 4a,b)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims
Create a free account to see all 156 claims and to verify the 28 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“the decrease in [3H]-labelled TG observed in Figure 3D”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“PC, PE and phosphatidylserine PS species all had significantly increased PUFA content (Fig 3d,e,f)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Hepatic plant sterol content of WT, whole body T39 knockout, LXRα knockout, and LXRα T39 double knockout mice fed HF/HC/BS diet for 6 weeks”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 4 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 4 Lxrα-/-T39+/+, and 6 Lxrα-/-T39+/+.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“Liver cell injury was assigned a score from 0 to 2 as follows:”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“majority of hepatocytes are ballooned = 3.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“T39-/- mice challenged with 3 weeks of the HF/HC/BS diet had a 42% increase in HDL cholesterol levels (ED Fig 2a)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“(a) HDL-cholesterol of WT and whole body T39 knockout mice fed chow or HF/HC/BS diet for 4 weeks, n=4 per genotype for chow, 5 per genotype for HF/HC/BS diet.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Absorption of [14C]cholesterol administered by gavage to WT and whole body T39 knockout with/without LXRα along with Poloxamer-407 injection to inhibit peripheral lipoprotein catabolism”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 3 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 3 Lxrα-/-T39+/+, and 5 Lxrα-/-T39+/+.”
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 2×
“Genome-wide association studies have uncovered a plethora of novel genetic loci associated with alterations in plasma lipoprotein levels 2,3 that have potential to provide insights into metabolic diseases such as atherosclerosis and fatty liver.”
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979
Self-citationLXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732 · cited 1×
“Also, LPCAT3 activity ameliorates ER stress 10 , which affects SREBP-1 processing 24 .”
Cited by
Items 101–106 of 106
Yu, Z., Mao, S., Song, Y., Meng, X., Yu, J., Zong, Z., Gao, T., & Chen, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861490
Low HDL and high HDL syndromes
Yamashita, S., & Matsuzawa, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00305-8
Self-citationWang, W., Zhang, Z.-Z., Wu, Y., Wang, R.-Q., Chen, J.-W., Chen, J., Zhang, Y., Chen, Y.-J., Geng, M., Xu, Z.-D., et al. (2018) · doi:10.3389/fphar.2018.00195.s001
A novel marine-derived hypocholesterolemic agent acts through a new PPARδ–FBXW7–SREBP1 pathway
Gu, T., Zhang, L.-S., Xie, D.-N., Zhang, X., Cai, J., Wu, X., She, J.-L., Yan, L.-Y., Tian, L.-M., Wei, C.-L., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110282
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639812
Metadata
- Authors
- Hsieh, J., Koseki, M., Molusky, M. M., Yakushiji, E., Ichi, I., Westerterp, M., Iqbal, J., Chan, R. B., Abramowicz, S., Tascau, L., Takiguchi, S., Yamashita, S., Welch, C. L., Di Paolo, G., Hussain, M. M., Lefkowitch, J. H., Rader, D. J., & Tall, A. R.
- Affiliations
- Columbia University (US)
- Ochanomizu University (JP)
- SUNY Downstate Health Sciences University (US)
- University of Pennsylvania (US)
- The University of Osaka (JP)
- Corresponding author
- Koseki, Masahiro
- Tall, Alan R.
- ORCID
- Venue
- Nature
- Published
- 2016-07
- Volume
- 535
- Issue
- 7611
- Pages
- 303-307
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4947007
- OpenAlex
- W2462155612
- Semantic Scholar
- ee2839ddad345c5575b31795e9c4343879125fb3
- Cited by
- 106
- References
- 38
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 8 · 2022: 6 · 2021: 22 · 2020: 13 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15K16203)
- National Heart, Lung, and Blood Institute (RC2HL101864, R01HL119830, P01HL087123, R01HL111398, HL007343, T32HL007343)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046900, DK-46900, R56DK046900, R29DK046900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- liver X receptor, atherosclerosis, steatohepatitis, non-alcoholic fatty liver disease, HDL cholesterol, ABCA1, ABCG5/8, dietary cholesterol absorption, SREBP1, Western diet
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 5, ATP Binding Cassette Transporter, Subfamily G, Member 8, Liver X Receptors, Animals, Bile Acids and Salts, Cholesterol, Dietary, Fatty Acids, Unsaturated, Fatty Liver, Female, Gene Expression Regulation, Ligands, Lipoproteins, Lipoproteins, HDL, Cholesterol, HDL, Lipoproteins, LDL, Male, Phosphatidylcholines, Receptors, LDL, ATP-Binding Cassette Transporters, Hepatocytes, Lipogenesis, Atherosclerosis, Mice, Sterol Regulatory Element Binding Protein 1, Ubiquitination, Protein Stability, Orphan Nuclear Receptors, Diet, High-Fat, Proteolysis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.